About
Antibodies, Small Molecules
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyVirginia, DC, DE & Maryland
Team (45)
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
276
By Phase
PHASE1: 1PHASE1/PHASE2: 2
By Status
RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06536101Lead Sponsor
The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407
PHASE1Completed
48 participants
Started: Sep 2, 2024 · Completed: Apr 5, 2025
NCT06425926Lead Sponsor
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
PHASE1/PHASE2Recruiting
117 participants
Started: May 9, 2024 · Completed: Nov 30, 2026
NCT06028074Lead Sponsor
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
PHASE1/PHASE2Recruiting
111 participants
Started: Dec 12, 2023 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...